tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Dec 6;8(4):E739.
doi: 10.3390/vaccines8040739.
Efforts at COVID-19 Vaccine Development: Challenges and Successes
Azizul Haque[SUP] 1 [/SUP], Anudeep B Pant[SUP] 2 [/SUP]
Affiliations
Abstract
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
Keywords: COVID-19 disease; pandemics; public health; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); trials; vaccines.
. 2020 Dec 6;8(4):E739.
doi: 10.3390/vaccines8040739.
Efforts at COVID-19 Vaccine Development: Challenges and Successes
Azizul Haque[SUP] 1 [/SUP], Anudeep B Pant[SUP] 2 [/SUP]
Affiliations
- PMID: 33291245
- DOI: 10.3390/vaccines8040739
Abstract
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
Keywords: COVID-19 disease; pandemics; public health; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); trials; vaccines.